Clinical Trial Update: A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT [Phase 3]

View source ↗

Summary

The Phase III DIAPREVENT trial evaluating Diamyd in patients newly diagnosed with Type 1 Diabetes Mellitus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Diamyd

Snippet

Sponsor: Diamyd Therapeutics AB | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: TERMINATED